ACP-105

ACP-105 is a selective androgen receptor modulator (SARM) that has been investigated for its potential to stimulate anabolic activity in specific tissues, such as muscle and bone, while theoretically minimizing androgenic side effects in other tissues, like the prostate or sebaceous glands. Developed in the early 2000s, it functions by selectively binding to androgen receptors. Preclinical research has explored its therapeutic potential in conditions associated with muscle wasting and bone demineralization. As a research chemical, its use in humans is not approved by regulatory bodies like the FDA for any medical indication. Therefore, information regarding its efficacy and safety in humans is primarily derived from preclinical studies and anecdotal reports, which are not a substitute for rigorous clinical trials. The compound is understood to have a relatively high binding affinity to the androgen receptor, similar to some endogenous androgens, which is a key aspect of its proposed mechanism of action (PubChem).